Abstract

Harrow Health Inc will report fiscal results on August 10, 2026 Post-Mkt; this preview summarizes consensus expectations for revenue, gross margin, net margin, and adjusted EPS, alongside business segment dynamics and analyst views for the upcoming quarter.

Market Forecast

- For the current quarter, market models project Harrow Health Inc revenue at 70.34 million US dollars, with an expected adjusted EPS of -0.18; EBIT is estimated at -1.05 million US dollars, and revenue is modeled to rise by 6.59% year over year. Forecast growth interpretations follow ratio-to-percentage scaling rules. - With revenue expected to expand and operating losses to narrow modestly, the gross margin outlook is supported by prior-quarter levels around 61.18%, while net margin remains pressured given a projected loss; adjusted EPS is guided to improve year over year. The company’s core “product sales” business remains the highlight, and management emphasis is on advancing its ophthalmic portfolio; the most promising area remains product sales, modeled at 70.34 million US dollars with 6.59% YoY growth.

Last Quarter Review

- In the prior reported quarter, Harrow Health Inc delivered 44.20 million US dollars of revenue, a gross profit margin of 61.18%, GAAP net profit attributable to shareholders of -27.60 million US dollars, a net margin of -62.44%, and adjusted EPS of -0.74, with revenue declining 7.59% year over year. Quarter-on-quarter net profit change was -516.57% based on tool convention. - Operating performance reflected a challenging mix of revenue softness against a high fixed-cost base, contributing to negative operating leverage; EBIT recorded -22.08 million US dollars with significant YoY contraction. The main business segment “product sales” generated 44.13 million US dollars, while “other” contributed 0.07 million US dollars; product sales dominated the revenue mix.

Current Quarter Outlook

Main business: Product sales trajectory and margin mix

Management’s core revenue engine remains product sales, with the forecast implying 70.34 million US dollars this quarter and a 6.59% year-over-year increase. Given the prior-quarter gross margin at 61.18%, even a modest revenue recovery can lift gross profit dollars, but the net margin will still be influenced by operating expense run-rate and any incremental launch or distribution costs. The breadth of the portfolio and channel execution are key to stabilizing growth and maintaining pricing, and any shifts in mix toward higher-margin ophthalmic products could support margin resilience.

Most promising business: Scaling revenue with gradual operating leverage

The most promising near-term lever is the expansion of the product sales line, which is expected to carry the entire top-line growth. At a modeled 70.34 million US dollars and 6.59% YoY growth, incremental contribution margin becomes the focal point; if gross margin holds near the low 60s and opex growth is contained, losses should narrow versus last year. Execution on supply continuity, formulary uptake, and prescriber adoption will determine whether gross-to-net dynamics remain favorable enough to improve EBIT from the -1.05 million US dollars projection.

Stock price drivers this quarter: Profit trajectory and operating discipline

Investors will key on the path of adjusted EPS relative to the -0.18 estimate, the cadence of EBIT improvement, and any signs that gross margin can sustain near or above the prior-quarter level. Commentary around inventory normalization, reimbursement trends, and SG&A efficiency will shape confidence in sequential operating leverage. A tighter working-capital cycle and clearer visibility into demand pacing could mitigate concerns raised by the previous quarter’s steep net loss, while confirmation of revenue growth within the guided range would anchor expectations.

Analyst Opinions

The prevailing analyst stance skews bullish, emphasizing the prospect of sequential improvement in operating performance and the durability of gross margins around the low 60s as revenue scales this quarter. Analysts highlight that the revenue base is broad enough within product sales to support mid-single-digit growth while management prioritizes expense control, aligning with the -1.05 million US dollars EBIT estimate and a narrower EPS loss of -0.18. Bullish commentary expects that maintaining gross-to-net stability and mix shifts toward higher-margin SKUs can support upside to EBIT and EPS if demand trends track above the modeled 6.59% YoY revenue growth.